首页> 美国卫生研究院文献>AAPS PharmSci >Use of Different Parameters and Equations for Calculation of IC50 Values in Efflux Assays: Potential Sources of Variability in IC50 Determination
【2h】

Use of Different Parameters and Equations for Calculation of IC50 Values in Efflux Assays: Potential Sources of Variability in IC50 Determination

机译:使用不同的参数和方程式进行外排测定法中IC50值的计算:IC50测定中潜在的变异性来源

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Drug interactions due to efflux transporters may result in one drug increasing or decreasing the systemic exposure of a second drug. The potential for in vivo drug interactions is estimated through in vitro cell assays. Variability in in vitro parameter determination (e.g., IC50 values) among laboratories may lead to different conclusions in in vivo interaction predictions. The objective of this study was to investigate variability in in vitro inhibition potency determination that may be due to calculation methods. In a Caco-2 cell assay, the absorptive and secretive permeability of digoxin was measured in the presence of spironolactone, itraconazole and vardenafil. From the permeability data, the efflux ratio and net secretory flux where calculated for each inhibitor. IC50 values were then calculated using a variety of equations and software programs. All three drugs decreased the secretory transport of digoxin in a concentration-dependent manner while increasing digoxin’s absorption to a lesser extent. The resulting IC50 values varied according to the parameter evaluated, whether percent inhibition or percent control was applied, and the computational IC50 equation. This study has shown that multiple methods used to quantitate the inhibition of drug efflux in a cell assay can result in different IC50 values. The variability in the results in this study points to a need to standardize any transporter assay and calculation methods within a laboratory and to validate the assay with a set of known inhibitors and non-inhibitors against a clinically relevant substrate.Electronic supplementary materialThe online version of this article (doi:10.1208/s12248-013-9554-7) contains supplementary material, which is available to authorized users.
机译:由于外排转运蛋白引起的药物相互作用可能导致一种药物增加或减少第二种药物的全身暴露。体内药物相互作用的潜力是通过体外细胞测定法估算的。实验室之间体外参数确定的可变性(例如IC50值)可能会导致体内相互作用预测的结论不同。这项研究的目的是调查可能由于计算方法而引起的体外抑制效能测定的变异性。在Caco-2细胞分析中,在存在螺内酯,伊曲康唑和伐地那非的情况下测量了地高辛的吸收和分泌通透性。根据渗透率数据,计算每种抑制剂的外排比和净分泌通量。然后使用各种方程式和软件程序计算IC50值。这三种药物都以浓度依赖的方式降低了地高辛的分泌运输,同时在较小程度上增加了地高辛的吸收。所得的IC50值根据所评估的参数(应用抑制百分比或控制百分比)以及计算的IC50公式而变化。该研究表明,在细胞测定中用于定量抑制药物外排的多种方法可导致不同的IC50值。本研究结果的差异表明需要在实验室内对任何转运蛋白测定和计算方法进行标准化,并需要使用针对临床相关底物的一组已知抑制剂和非抑制剂来验证该测定方法。本文(doi:10.1208 / s12248-013-9554-7)包含补充材料,授权用户可以使用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号